This series on “Future Directions for Mantle Cell Lymphoma” is edited by Dr. Martin Dreyling, from Medizinische Klinik III der Universität München-Grosshadern, München, Germany.
Review Article on Future Directions for Mantle Cell Lymphoma
Mantle cell lymphoma pathology update in the 2016 WHO classification
Risk stratification of mantle cell lymphoma (MCL)
Minimal residual disease (MRD) in mantle cell lymphoma
Recent advances in the first-line treatment of mantle cell lymphoma
Front-line therapy in elderly patients with mantle cell lymphoma
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
Venetoclax for the treatment of mantle cell lymphoma
Immunologic treatment strategies in mantle cell lymphoma: checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engager (BiTE) molecules
Targeting CDK4/6 in mantle cell lymphoma
Tailored treatment in mantle cell lymphoma
Disclosure:
The series “Future Directions for Mantle Cell Lymphoma” was commissioned by the editorial office, Annals of Lymphoma without any sponsorship or funding. Martin Dreyling served as the unpaid Guest Editor for the series.